Why Pancreatic Cancer Is So Hard to Beat
Pancreatic cancer has one of the lowest survival rates of any major cancer. Deep inside the abdomen and nearly invisible in its early stages, it evades detection until it has already spread. New KRAS-targeted therapies are finally offering hope.
A Silent Killer Hidden Deep in the Body
Of all common cancers, few inspire as much dread among oncologists as pancreatic cancer. With a five-year survival rate of just 13 percent, it kills roughly four out of five patients within a year of diagnosis. It is the third-leading cause of cancer death in the United States, yet it receives a fraction of the research funding devoted to more survivable malignancies. Understanding why this cancer is so lethal — and what is finally changing — starts with the organ itself.
Why Detection Comes Too Late
The pancreas sits deep in the retroperitoneal space, tucked behind the stomach and surrounded by the liver, spleen, and small intestine. Unlike a breast lump or a skin lesion, a pancreatic tumour cannot be seen or felt during a routine physical exam. There is no standard screening test for the general population — no equivalent of a mammogram or colonoscopy — because imaging modalities like CT and MRI lack the sensitivity to catch small, early-stage lesions cost-effectively.
The symptoms that eventually appear — jaundice, unexplained weight loss, abdominal pain radiating to the back, greasy stools — are vague and easily mistaken for other conditions. By the time a diagnosis is made, roughly 80 percent of patients already have locally advanced or metastatic disease, making curative surgery impossible.
A Hostile Microenvironment
Even when detected, pancreatic ductal adenocarcinoma (PDAC) — the most common form, accounting for about 90 percent of cases — is notoriously resistant to treatment. The tumour surrounds itself with a dense layer of scar-like tissue called desmoplastic stroma, which acts as a physical barrier. This fibrous shield blocks chemotherapy drugs from penetrating the tumour and suppresses the immune cells that would otherwise attack it.
The result is a microenvironment that is simultaneously hostile to the immune system and protective of cancer cells — a biological fortress that has frustrated oncologists for decades.
The KRAS Problem — and Its Solution
At the genetic level, pancreatic cancer is driven almost universally by a single culprit: mutations in the KRAS gene. Found in over 90 percent of PDAC tumours, KRAS mutations lock a growth-signalling protein into a permanently "on" position, telling cells to divide without restraint. The most common variant, KRAS G12D, appears in about 40 percent of cases.
For decades, KRAS was considered "undruggable" — the protein's smooth surface offered no obvious pocket for a drug molecule to latch onto. That changed with a new generation of targeted therapies. Drugs like daraxonrasib and setidegrasib now attack specific KRAS mutations directly — either blocking the protein or flagging it for destruction by the body's own cellular machinery.
In a Phase 3 trial, daraxonrasib doubled median survival compared with standard chemotherapy (13.2 months versus 6.7 months) and cut the risk of death by 60 percent. Another drug, elraglusib, doubled one-year survival rates when combined with chemotherapy.
Why Progress Has Been Slow — and What Comes Next
Despite these advances, pancreatic cancer remains exceptionally difficult to treat. Several factors compound the challenge:
- Genetic complexity: Beyond KRAS, tumours accumulate mutations in suppressor genes like TP53 and SMAD4, enabling resistance to single-target drugs.
- Metabolic adaptability: Pancreatic cancer cells reprogram their metabolism to thrive in low-oxygen, nutrient-poor conditions that would starve normal cells.
- Immune evasion: The desmoplastic stroma and immunosuppressive signalling make checkpoint immunotherapies — which have revolutionised melanoma and lung cancer — largely ineffective against PDAC.
Researchers are now pursuing combination strategies: pairing KRAS inhibitors with immunotherapy, targeting the stromal barrier, and developing liquid biopsy blood tests that could detect circulating tumour DNA long before symptoms appear.
The five-year survival rate has nearly doubled over the past decade — from 7 percent to 13 percent — a modest but meaningful gain. With KRAS finally cracked and early-detection research accelerating, oncologists say the next decade could bring the most significant progress yet against one of medicine's most stubborn adversaries.
